Zacks Investment Research
News Agency

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
Source:
Zacks Investment Research
Visit Source
Comments